EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Hepatitis B Reactivation and Infection in People with HIV on Tenofovir-Sparing Antiretroviral Therapy

G C Haser, N E Lisha, H N Kim, G Burkholder, E R Cachay, H M Crane, J A C Delaney, O Falade-Nwulia, J Fleming, M M Kitahata, A C Pettit, S E Rutstein, G Yendewa, A F Luetkemeyer, K A Christopoulos

Open Forum Infectious Diseases · 2026-11-07

DOI: 10.1093/ofid/ofag731 ↗
AbstractBibliografische Angaben

Abstract

Abstract Background As more people with HIV (PWH) transition to tenofovir (TXF)-sparing antiretroviral therapy (ART), the risk of hepatitis B virus (HBV) reactivation (HBVr) and new infection (HBVi) is a concern. Methods We conducted a retrospective study of 5,776 PWH in the Centers for AIDS Research Network of Integrated Clinical Systems cohort without active HBV infection with ≥1 TXF-sparing ART regimen prescribed after 5/1/2014 and examined episodes of HBVi/r defined as new HBV surface antigen (HBsAg) positivity or HBV viremia. We calculated rate of HBVi/r over total time on TXF-sparing ART per 10,000 person-years. Results We identified 17 cases of HBVi/r over a median 5.3 years of follow up. The rate of HBVi was 3.9 per 10,000 person-years, and rate of HBVr was 6.0 per 10,000 person-years, with possible higher risk for those who were HBV surface antibody (HBsAb) negative at cohort entry and among those not on ART with no anti-HBV activity. Liver injury, defined as alanine aminotransferase lab value ≥ 100 U/L, occurred within 3 months in only one HBVi case. Conclusions HBVi/r on TXF-sparing ART was rare in this U.S. cohort. HBVi/r occurred in some with prior HBsAb positivity, but significant hepatic flares were not observed. When starting TXF-sparing ART, providers should check complete HBV serologies, offer initial or additional vaccination as needed, and monitor for potential HBVi/r.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →